The new world of medicine: AI doctors
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 hours ago
- Business Wire
Paige and Oncoclínicas Strengthen Leadership in AI-Driven Cancer Diagnostics Across Brazil
NEW YORK & SíO PAULO--(BUSINESS WIRE)--Paige, a leader in next-generation AI technology, announced the continued and expanded use of its innovative AI-assisted diagnostic applications by long-time customer, Oncoclínicas&Co (Oncoclínicas), the largest private group of cancer care in Latin America. With a commitment to enhancing diagnostic capabilities and improving patient safety, Oncoclínicas has utilized Paige's technology across prostate and breast cancer diagnosis, supporting its commitment to advancing pathology standards throughout Brazil. Oncoclínicas employs a rigorous approach where all digitized prostate and breast cancer biopsy whole-slide images are analyzed by pathologists using AI as an adjunct diagnostic tool. This process provides extra layers of patient safety, enhancing both sensitivity and efficiency for the pathologists using the technology. Since August 2021, Oncoclínicas has utilized AI to support the review of over 23,000 prostate and breast biopsies. These results demonstrate the scale and commitment of Oncoclínicas to AI integration in their diagnostic workflow, which has led to Oncoclínicas' achieving: Faster second reader sign-out for senior pathologists using FullFocus™ and AI support. 1 Enhanced detection rates, including the identification of approximately .5% of precursor non-obligatory breast lesions that were not initially detected by pathologists. 1 Improved diagnostic consistency and efficiency through the use of Paige Prostate and Paige Breast AI Suites. 1 Dr. Leonard Medeiros da Silva, pathologist at OC Medicina de Precisão, an integrated laboratory of Oncoclínicas&Co dedicated to pathological anatomy, genetic testing and Big Data, reports a positive experience with Paige Prostate. "It aligns with Oncoclínicas published data showing nearly 100% sensitivity and 93% specificity,' he notes. 'The specialist also commends the technology's effectiveness in both cancer detection and accurate Gleason score determination.' 'We are proud to support Oncoclínicas in their mission to offer cutting-edge cancer diagnostic solutions,' said Dr. Juan Retamero, Medical Vice President at Paige. 'Their success in implementing AI technology is a testament to their dedication to clinical excellence and their forward-thinking approach to pathology. Our long-term partnership underscores Paige's commitment to providing access to high-quality AI technology globally, helping pathologists provide better diagnoses for their patients.' 'Over the past few months, I've had the opportunity to witness how the integration of digital pathology, biomarkers, AI, and genomics is accelerating the advancement of precision medicine, and, more importantly, improving patients' quality of life and offering new hope in the fight against cancer,' said Rodrigo Alvarenga, Operations Executive at Oncoclínicas&Co. 'At both the 2025 USCAP in Boston and ASCO in Chicago, it became clear that precision medicine is no longer a distant goal, but a present-day reality that can expand access to advanced technologies and enable more cost-effective care. We've reached an exciting point of no return, the convergence of AI, pathology, and genomics is not only transforming cancer care but is also critical to the long-term sustainability of our healthcare systems.' In Brazil, FullFocus™ and all AI assisted diagnostic applications such as the Paige Prostate Suite and the Paige Breast Suite are for Research Use Only. Not for use in diagnostic procedures. 1 Figures are based on independent clinical research conducted by Oncoclínicas&Co. Finding an average of 12,000 breast biopsies and surgical specimens were analyzed in 2024. The Paige Breast Suite as a second reader detected 55 non-obligatory precursor breast lesions that were not initially detected by pathologists. Additionally, after utilizing FullFocus™ with the Paige Prostate Suite, the average time to read a slide and complete a report reduced to one minute and 10 seconds. About Oncoclínicas&Co Oncoclínicas&Co is the largest group dedicated to cancer treatment in Latin America, with a highly specialized and innovative model focused on the oncology journey. With a medical staff of over 2,900 oncology specialists, the company operates in 40 Brazilian cities, totaling more than 140 units. Focused on research, technology, and innovation, the group has conducted approximately 682,000 treatments in the past 12 months. Oncoclínicas follows international standards of excellence, integrating outpatient clinics with high-complexity cancer centers, enhancing treatment through precision medicine and genomics. As the exclusive partner of the Dana-Farber Cancer Institute in Brazil, affiliated with Harvard Medical School, it has acquired Boston Lighthouse Innovation (USA) and holds a stake in MedSir (Spain). It is also part of the IDIVERSA index of B3, reinforcing its commitment to diversity. With the goal of expanding its global mission to overcome cancer, Oncoclínicas has entered Saudi Arabia through a joint venture with the Al Faisaliah Group, bringing its oncology expertise to a new continent. Learn more at: About Paige Paige is pushing the boundaries of AI to solve cancer's most critical issues, revolutionizing cancer care with next-generation technology. By leveraging exclusive access to millions of digitized pathology slides, clinical reports, and genomic data, Paige gains a holistic understanding of cancer, encompassing diverse factors such as gender, race, ethnicity, and geographical regions. This comprehensive data enables Paige to create advanced AI solutions that redefine cancer detection, diagnosis, and treatment. With a unique, intricate understanding of tissue, Paige sets new standards in precision diagnostics, earning the distinction of being the first FDA-cleared AI application in pathology. Paige has also developed the first million-slide foundation model for cancer, continuing to lead the way in uncovering novel insights and transforming them into life-changing products. For more information, visit
Business Wire
4 hours ago
- Business Wire
Viz.ai Announces CMS Reimbursement Pathway for Hypertrophic Cardiomyopathy via AI-Enhanced Electrocardiogram
SAN FRANCISCO--(BUSINESS WIRE)-- the leader in AI-powered disease detection and intelligent care coordination, today announced that the Category III CPT codes for AI-enabled electrocardiogram (ECG) analysis accepted and established by the American Medical Association (AMA) CPT Editorial Panel establish a national reimbursement framework for AI algorithms that perform ECG analysis for cardiac pathology, including conditions like hypertrophic cardiomyopathy (HCM), for which Viz HCM was designed. The Centers for Medicare & Medicaid Services established a Medicare rate of $128.90, effective January 1, 2025, for CPT codes 0764T and 0765T which apply to 'electrocardiograph, computerized analysis with artificial intelligence, for detection of cardiac pathology, with physician or other qualified health care professional interpretation and report' related to concurrently performed ECG or previously performed ECG respectively. These codes facilitate national reimbursement for AI algorithms like Viz HCM, which analyzes 12-lead ECGs to identify patterns consistent with HCM, a condition that often goes undiagnosed until serious complications arise. 'This is a major milestone for AI in cardiovascular care,' said Jamie Stern, senior director of Care Pathways at 'Reimbursement for AI-powered ECG interpretation empowers clinicians to identify high-risk patients earlier, before symptoms progress or serious events occur—supporting more timely diagnosis, specialist referral, and treatment.' Hypertrophic cardiomyopathy is one of the most common inherited heart conditions and a leading cause of sudden cardiac death, particularly in younger adults. Yet the majority of individuals living with HCM are undiagnosed. Viz HCM uses deep learning to flag patients at risk based on ECG data captured across a healthcare system in routine clinical workflows, advancing early detection and closing critical gaps in care. A recent study, published in JACC: Clinical Electrophysiology, demonstrated that Viz HCM achieved a high degree of accuracy in detecting HCM 1. The AI-ECG successfully identified 574 HCM patients, and in 691 cases where HCM was not identified the AI-ECG assisted in identifying alternate clinically relevant diagnosis, highlighting Viz HCM's value for more effective disease detection. "Reimbursement is a meaningful step forward for the uptake of novel technologies,' said Joshua M. Lampert, MD, FACC, cardiac electrophysiologist and medical director of Machine Learning at Mount Sinai Fuster Heart Hospital. 'This development can provide institutions with a sustainable means to build and maintain the necessary infrastructure to provide safe and effective care for patients during an actively evolving healthcare modernization process." The CPT codes 0764T and 0765T were first published in the CPT 2023 code set, effective for use on or after January 1, 2023. However, CMS had not established a national payment for these codes until January 1, 2025. This development enables physicians and health systems to integrate reimbursable AI-based ECG interpretation into routine care delivery. Viz HCM is part of the One Platform, which connects disparate data and care teams in real time to accelerate diagnosis, streamline care coordination, and improve outcomes across a range of cardiovascular and neurological conditions. 1 Desai, M. Y., Rutkowski, K., Ospina, S., et al. (2025). Real‑world artificial intelligence–based electrocardiographic analysis to diagnose hypertrophic cardiomyopathy. JACC: Clinical Electrophysiology, 11(6). About is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care across 1,800 hospitals and health systems in the U.S. and Europe. The AI-powered One® is an intelligent care coordination solution that identifies more patients with a suspected disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by real-world clinical evidence, One delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information visit
Yahoo
5 hours ago
- Yahoo
SIGA to Host Business Update Call on August 5, 2025 Following Release of Second-Quarter 2025 Results
NEW YORK, July 29, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Tuesday, August 5, 2025. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer. A live webcast of the call will also be available on the Company's website at in the Investor Relations section of the site, or by clicking here. Please log in approximately 5-10 minutes prior to the scheduled start time. Participants may access the call by dialing 1-800-717-1738 for domestic callers or 1-646-307-1865 for international callers. A replay of the call will be available for two weeks by dialing 1-844-512-2921 for domestic callers or 1-412-317-6671 for international callers and using Conference ID: 1130215. The archived webcast will be available in the Investor Relations section of the Company's website. About SIGA SIGA is a commercial-stage pharmaceutical company and leader in global health focused on the development of innovative medicines to treat and prevent infectious diseases. With a primary focus on orthopoxviruses, we are dedicated to protecting humanity against the world's most severe infectious diseases, including those that occur naturally, accidentally, or intentionally. Through partnerships with governments and public health agencies, we work to build a healthier and safer world by providing essential countermeasures against these global health threats. Our flagship product, TPOXX® (tecovirimat), is an antiviral medicine approved in the U.S. and Canada for the treatment of smallpox and authorized in Europe, the UK, and Japan for the treatment of smallpox, mpox (monkeypox), cowpox, and vaccinia complications. For more information about SIGA, visit Contacts:Suzanne Harnettsharnett@ and Investors Media Jennifer Drew-Bear, Edison GroupJdrew-bear@ Holly Stevens, CG Lifehstevens@
